Analyst picks & changes

The Liposome Co.

(LIPO)

Mabon Securities analyst Marc Ostro started coverage with a "buy," describing LIPO as a market anomaly: a company with advanced-stage

Read the full 246 word article

How to gain access

Continue reading with a
two-week free trial.